Comparative Pharmacology
Head-to-head clinical analysis: DYANAVEL XR 10 versus EVEKEO ODT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYANAVEL XR 10 versus EVEKEO ODT.
DYANAVEL XR 10 vs EVEKEO ODT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dyanavel XR is a central nervous system stimulant that increases extracellular levels of dopamine and norepinephrine by inhibiting their reuptake and enhancing their release from presynaptic neurons.
EVEKEO ODT (amphetamine) is a CNS stimulant that increases extracellular levels of dopamine and norepinephrine by blocking their reuptake into presynaptic neurons and inhibiting monoamine oxidase, leading to enhanced neurotransmission.
Recommended starting dose for adults is 10 mg orally once daily in the morning. May increase in increments of 5-10 mg at weekly intervals based on tolerability and response. Maximum recommended dose is 60 mg/day.
0.25 mg orally as a single dose; may repeat once after 30 minutes if required.
None Documented
None Documented
12 hours (amphetamine); clinical context: extended-release profile allows once-daily dosing
3-5 hours in healthy adults; prolonged in renal impairment (up to 20 hours in ESRD)
Renal (80-90% as unchanged drug); fecal (minor, 1-5%)
Renal: approximately 50% as unchanged drug and metabolites; fecal: minimal (<10%)
Category C
Category C
CNS Stimulant
CNS Stimulant